NVG-291 in Spinal Cord Injury Subjects
← catalyst calendarSponsored by NervGen Pharma (industry) · NGEN — their whole pipeline →.
Phase
Phase 1/2
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
24actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-08-08 | actual | When the study began enrolling |
| Primary completion | 2025-12-31 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-01-21 | actual | The whole study's end, after follow-up |
| First posted | 2023-07-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Spinal Cord Injuries
- Chronic Spinal Cord Injury
- Subacute Spinal Cord Injury
Intervention
- Drug: NVG-291
Primary outcome
what the primary-completion date above is the date OFElectrophysiological
measured 12 weeks
Publications
- PMID 40744729 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · NGEN's whole pipeline · Catalyst calendar · Every registered study · What changed